This is a prospective, single-center, single-arm, phase II clinical study. The primary purpose of the study was to evaluate the efficacy and safety of radiotherapy with sequential albumin-bound paclitaxel + Gemcitabine chemotherapy + anti-PD-1 monoclonal antibody and Thymalfasin for borderline resectable pancreatic cancer, and to explore clinical indicators related to efficacy, further guiding subsequent individualized precise treatment.
Age ≥ 18 years, with ECOG score of 0 ~ 1;
Histologically or cytologically confirmed diagnosis of ductal adenocarcinoma of pancreas;
Classification as borderline resectable pancreatic cancer according to the NCCN Guidelines (2024 Edition);
Deemed suitable for neoadjuvant therapy following discussion by the MDT team of the study site;
Prior systemic anti-tumor therapy;
Prior medical history of other tumors, except for cervical carcinoma in situ, treated squamous cell carcinoma or urothelial bladder carcinoma (Ta and TIS), or other malignant tumors that have received radical treatment (at least 5 years prior to enrollment);
Prior history of abdominal radiotherapy;
Subjects with active bacterial or fungal infection (≥ Grade 2 as per NCI-CTC, Version 3).